ArticleQuantitative imaging in medicine and surgery2025
Quantitative metrics of mean apparent propagator magnetic resonance imaging in the diagnosis of axillary lymph node metastasis in breast cancer.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnosis of axillary lymph nodes (ALNs) status using only morphological criteria or conventional apparent diffusion coefficient (ADC) value is not sufficiently accurate. Mean apparent propagator (MAP) magnetic resonance imaging (MRI) offers the potential for discriminating metastatic and nonmetastatic ALNs. Therefore, our aim was to evaluate the diagnostic performance of MAP-MRI quantitative metrics in discriminating between metastatic and nonmetastatic ALNs in breast cancer patients. Methods: This prospective study enrolled 145 participants (mean age, 49±10 years) with breast cancer from December 2021 to February 2023 who underwent diffusion spectrum imaging and conventional MRI. All participants received ultrasound (US)-guided ALN biopsy or sentinel lymph node biopsy (SLNB) and were divided into metastatic (n=53) and nonmetastatic (n=92) ALN groups based on pathology. The MAP-MRI metrics derived from diffusion spectrum imaging and the ADC value derived from conventional diffusion-weighted imaging (DWI) were measured. The MRI morphologic features of all target ALNs were assessed. The area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy were calculated to evaluate diagnostic performance. Results: Six diffusion MRI metrics, namely, the MAP_non-Gaussianity (NG), MAP_axial non-Gaussianity (NG Conclusions: The MAP-MRI metric has superior performance to the ADC value and MRI morphologic assessment in identifying metastatic ALN in breast cancer patients for optimizing the diagnostic work-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.